<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Digit Health</journal-id><journal-id journal-id-type="iso-abbrev">Digit Health</journal-id><journal-id journal-id-type="pmc-domain-id">3398</journal-id><journal-id journal-id-type="pmc-domain">dghealth</journal-id><journal-id journal-id-type="publisher-id">DHJ</journal-id><journal-title-group><journal-title>Digital Health</journal-title></journal-title-group><issn pub-type="epub">2055-2076</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10291536</article-id><article-id pub-id-type="pmcid-ver">PMC10291536.1</article-id><article-id pub-id-type="pmcaid">10291536</article-id><article-id pub-id-type="pmcaiid">10291536</article-id><article-id pub-id-type="pmid">37377562</article-id><article-id pub-id-type="doi">10.1177/20552076231182807</article-id><article-id pub-id-type="publisher-id">10.1177_20552076231182807</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Protocol</subject></subj-group></article-categories><title-group><article-title>Cocreation of a conversational agent to help patients adhere to their varenicline treatment: A study protocol</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8179-3628</contrib-id><name name-style="western"><surname>Minian</surname><given-names initials="N">Nadia</given-names></name><xref rid="aff1-20552076231182807" ref-type="aff">1</xref><xref rid="aff2-20552076231182807" ref-type="aff">2</xref><xref rid="aff3-20552076231182807" ref-type="aff">3</xref><xref rid="aff4-20552076231182807" ref-type="aff">4</xref><xref rid="aff5-20552076231182807" ref-type="aff">5</xref><xref rid="corresp1-20552076231182807" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mehra</surname><given-names initials="K">Kamna</given-names></name><xref rid="aff1-20552076231182807" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rose</surname><given-names initials="J">Jonathan</given-names></name><xref rid="aff6-20552076231182807" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Veldhuizen</surname><given-names initials="S">Scott</given-names></name><xref rid="aff1-20552076231182807" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zawertailo</surname><given-names initials="L">Laurie</given-names></name><xref rid="aff1-20552076231182807" ref-type="aff">1</xref><xref rid="aff3-20552076231182807" ref-type="aff">3</xref><xref rid="aff4-20552076231182807" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ratto</surname><given-names initials="M">Matt</given-names></name><xref rid="aff7-20552076231182807" ref-type="aff">7</xref><xref rid="aff8-20552076231182807" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lecce</surname><given-names initials="J">Julia</given-names></name><xref rid="aff1-20552076231182807" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Selby</surname><given-names initials="P">Peter</given-names></name><xref rid="aff1-20552076231182807" ref-type="aff">1</xref><xref rid="aff2-20552076231182807" ref-type="aff">2</xref><xref rid="aff3-20552076231182807" ref-type="aff">3</xref><xref rid="aff9-20552076231182807" ref-type="aff">9</xref><xref rid="aff10-20552076231182807" ref-type="aff">10</xref></contrib></contrib-group><aff id="aff1-20552076231182807"><label>1</label>INTREPID Lab (formerly Nicotine Dependence Service), Centre for Addiction and Mental Health, Toronto, ON, Canada</aff><aff id="aff2-20552076231182807"><label>2</label>Department of Family and Community Medicine, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, ON, Canada</aff><aff id="aff3-20552076231182807"><label>3</label>Campbell Family Mental Health Research Institute, <institution-wrap><institution-id institution-id-type="Ringgold">7978</institution-id><institution content-type="university">Centre for Addiction and Mental Health</institution></institution-wrap>, Toronto, ON, Canada</aff><aff id="aff4-20552076231182807"><label>4</label>Department of Pharmacology and Toxicology, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, ON, Canada</aff><aff id="aff5-20552076231182807"><label>5</label>Institute of Medical Sciences, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, ON, Canada</aff><aff id="aff6-20552076231182807"><label>6</label>Edward S. Rogers Sr. Department of Electrical and Computer Engineering, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, ON, Canada</aff><aff id="aff7-20552076231182807"><label>7</label>Faculty of Information, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, ON, Canada</aff><aff id="aff8-20552076231182807"><label>8</label>Schwartz Reisman Institute for Technology and Society, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, ON, Canada</aff><aff id="aff9-20552076231182807"><label>9</label>Dalla Lana School of Public Health, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, ON, Canada</aff><aff id="aff10-20552076231182807"><label>10</label>Department of Psychiatry, <institution-wrap><institution-id institution-id-type="Ringgold">7938</institution-id><institution content-type="university">University of Toronto</institution></institution-wrap>, Toronto, ON, Canada</aff><author-notes><corresp id="corresp1-20552076231182807">Nadia Minian, 1025 Queen Street West, Toronto, Ontario M6J1H1, Canada. 
Email: <email>Nadia.Minian2@camh.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2023</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">425542</issue-id><elocation-id>20552076231182807</elocation-id><history><date date-type="received"><day>16</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>1</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>27</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-27 14:25:21.070"><day>27</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_20552076231182807.pdf"/><abstract><sec><title>Objective</title><p>Varenicline is the most efficacious approved smoking cessation medication, making it one of the most cost-effective clinical interventions for reducing tobacco-related morbidity and mortality. Adhering to varenicline is strongly associated with smoking cessation. Healthbots have the potential to help people adhere to their medications by scaling up evidence-based behavioral interventions. In this protocol, we outline how we will follow the UK's Medical Research Council's guidance to codesign a theory-informed, evidence-based, and patient-centered healthbot to help people adhere to varenicline.</p></sec><sec><title>Methods</title><p>The study will utilize the Discover, Design and Build, and Test framework and will include three phases: (a) a rapid review and interviews with 20 patients and 20 healthcare providers to understand barriers and facilitators to varenicline adherence (Discover phase); (b) Wizard of Oz test to design the healthbot and get a sense of the questions that chatbot has to be able to answer (Design phase); and (c) building, training, and beta-testing the healthbot (Building and Testing phases) where the Nonadoption, Abandonment, Scale-up, Spread, and Sustainability framework will be used to develop the healthbot using the simplest sensible solution, and 20 participants will beta test the healthbot. We will use the Capability, Opportunity, Motivation-Behavior (COM-B) model of behavior change and its associated framework, the Theoretical Domains Framework, to organize the findings.</p></sec><sec><title>Conclusions</title><p>The present approach will enable us to systematically identify the most appropriate features for the healthbot based on a well-established behavioral theory, the latest scientific evidence, and end users&#8217; and healthcare providers&#8217; knowledge.</p></sec></abstract><kwd-group><kwd>Medication adherence</kwd><kwd>smoking cessation</kwd><kwd>varenicline</kwd><kwd>healthbot</kwd><kwd>co-creation</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-20552076231182807"><funding-source id="funding1-20552076231182807"><institution-wrap><institution>Canadian Cancer Society</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000147</institution-id></institution-wrap></funding-source><award-id rid="funding1-20552076231182807">707218</award-id></award-group><award-group id="award2-20552076231182807"><funding-source id="funding2-20552076231182807"><institution-wrap><institution>Canadian Institutes of Health Research</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000024</institution-id></institution-wrap></funding-source><award-id rid="funding2-20552076231182807">PJT 180405</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-20552076231182807"><title>Introduction</title><p>Smoking cessation treatment is one of the most cost-effective clinical interventions for reducing cancer morbidity and mortality.<sup><xref rid="bibr1-20552076231182807" ref-type="bibr">1</xref>,<xref rid="bibr2-20552076231182807" ref-type="bibr">2</xref></sup> Of the approved smoking cessation medications, varenicline is one of the most effective.<sup>
<xref rid="bibr3-20552076231182807" ref-type="bibr">3</xref>
</sup> While several pharmacological interventions for smoking cessation work better for men than for women,<sup><xref rid="bibr4-20552076231182807" ref-type="bibr">4</xref>,<xref rid="bibr5-20552076231182807" ref-type="bibr">5</xref></sup> studies have shown that varenicline is equally effective in both genders for achieving 1-year abstinence.<sup>
<xref rid="bibr6-20552076231182807" ref-type="bibr">6</xref>
</sup> Thus, varenicline may help reduce gender disparities typically seen in rates of smoking cessation.<sup>
<xref rid="bibr6-20552076231182807" ref-type="bibr">6</xref>
</sup></p><p>As with many medications, adherence to varenicline is low,<sup><xref rid="bibr7-20552076231182807" ref-type="bibr">7</xref>,<xref rid="bibr8-20552076231182807" ref-type="bibr">8</xref></sup> and poor medication adherence is associated with lower smoking abstinence.<sup><xref rid="bibr9-20552076231182807" ref-type="bibr">9</xref><xref rid="bibr10-20552076231182807" ref-type="bibr"/><xref rid="bibr11-20552076231182807" ref-type="bibr"/><xref rid="bibr12-20552076231182807" ref-type="bibr"/>&#8211;<xref rid="bibr13-20552076231182807" ref-type="bibr">13</xref></sup> Evidence from clinical trials shows that over 30% of people taking varenicline are nonadherent by their second week of treatment,<sup>
<xref rid="bibr14-20552076231182807" ref-type="bibr">14</xref>
</sup> and those who are nonadherent are significantly less likely to be abstinent at multiple time points.<sup><xref rid="bibr12-20552076231182807" ref-type="bibr">12</xref>,<xref rid="bibr14-20552076231182807" ref-type="bibr">14</xref><xref rid="bibr15-20552076231182807" ref-type="bibr"/>&#8211;<xref rid="bibr16-20552076231182807" ref-type="bibr">16</xref></sup> Researchers have also shown that age and gender are significant factors that influence adherence to smoking cessation pharmacotherapies, with individuals of older age<sup>
<xref rid="bibr8-20552076231182807" ref-type="bibr">8</xref>
</sup> and males more likely to adhere.<sup><xref rid="bibr17-20552076231182807" ref-type="bibr">17</xref><xref rid="bibr18-20552076231182807" ref-type="bibr"/><xref rid="bibr19-20552076231182807" ref-type="bibr"/>&#8211;<xref rid="bibr20-20552076231182807" ref-type="bibr">20</xref></sup></p><p>A 2019 Cochrane review found that interventions that provided tailored behavioral supports improved adherence to smoking cessation medications.<sup><xref rid="bibr21-20552076231182807" ref-type="bibr">21</xref>,<xref rid="bibr22-20552076231182807" ref-type="bibr">22</xref></sup> However, there is a need for proper implementation of such novel interventions.<sup>
<xref rid="bibr23-20552076231182807" ref-type="bibr">23</xref>
</sup></p><p>The use of new technologies has been recognized as essential to achieving personalized, evidence-based, and economically viable healthcare.<sup>
<xref rid="bibr24-20552076231182807" ref-type="bibr">24</xref>
</sup> Advances in natural language processing and near-universal access to smart phone-based messaging systems provide a unique opportunity to connect with patients on a large scale. Simple electronic reminders, such as text messages, have shown improvement in medication adherence<sup>
<xref rid="bibr25-20552076231182807" ref-type="bibr">25</xref>
</sup> but only provide a solution to part of the problem, unintentional nonadherence. In order to provide a more comprehensive solution, one that embeds the behavior change interventions outlined in the Cochrane review,<sup>
<xref rid="bibr21-20552076231182807" ref-type="bibr">21</xref>
</sup> a more complex intervention, with several interacting components,<sup>
<xref rid="bibr26-20552076231182807" ref-type="bibr">26</xref>
</sup> is needed.</p><p>Digital health applications (e.g. text messaging and phone applications), focused on helping people adhere to varenicline, have shown promise;<sup><xref rid="bibr27-20552076231182807" ref-type="bibr">27</xref><xref rid="bibr28-20552076231182807" ref-type="bibr"/>&#8211;<xref rid="bibr29-20552076231182807" ref-type="bibr">29</xref></sup> however, they have not been able to tailor to the needs of each user, something that has been proposed as an important mechanism to improve medication adherence.<sup>
<xref rid="bibr30-20552076231182807" ref-type="bibr">30</xref>
</sup> Health-focused apps that have incorporated conversational agents (&#8220;healthbots&#8221;) might offer a solution, as they can provide tailored behavioral supports by tracking a patient's medication regimen, offering reminders, and answering questions about medication use, including common side effects. Healthbots are computer programs that mimic conversation with users using text or spoken language.<sup>
<xref rid="bibr31-20552076231182807" ref-type="bibr">31</xref>
</sup></p><p>When designing a healthbot, it is important to focus on developing an appealing and easy-to-use product, grounded in knowledge about the people and contexts where the innovation will ultimately be deployed.<sup>
<xref rid="bibr32-20552076231182807" ref-type="bibr">32</xref>
</sup> Equally important is to anchor a theoretical underpinning to the intervention,<sup><xref rid="bibr33-20552076231182807" ref-type="bibr">33</xref>,<xref rid="bibr34-20552076231182807" ref-type="bibr">34</xref></sup> especially given that the lack of a theoretical base in smoking cessation programs and in adherence interventions has been identified as a gap which might affect the interventions&#8217; success and effectiveness.<sup><xref rid="bibr35-20552076231182807" ref-type="bibr">35</xref><xref rid="bibr36-20552076231182807" ref-type="bibr"/><xref rid="bibr37-20552076231182807" ref-type="bibr"/>&#8211;<xref rid="bibr38-20552076231182807" ref-type="bibr">38</xref></sup> The development of the healthbot will follow the guidance of the UK Medical Research Council on complex interventions, which advocates selecting components of a complex intervention by using both theory and evidence and suggests this is done in a number of iterative phases with feedback loops. The <italic toggle="yes">Discover</italic>, <italic toggle="yes">Design</italic> and <italic toggle="yes">Build</italic>, and <italic toggle="yes">Test</italic> framework<sup>
<xref rid="bibr39-20552076231182807" ref-type="bibr">39</xref>
</sup> provides a practical way to design and study the healthbot, and the Capability, Opportunity, Motivation-Behavior (COM-B) model of behavior change<sup>
<xref rid="bibr40-20552076231182807" ref-type="bibr">40</xref>
</sup> and its associated framework (Theoretical Domain Framework)<sup>
<xref rid="bibr41-20552076231182807" ref-type="bibr">41</xref>
</sup> and taxonomy (behavior change technique taxonomy)<sup>
<xref rid="bibr42-20552076231182807" ref-type="bibr">42</xref>
</sup> provide a validated framework for behavior change, to identify and situate the &#8220;active ingredients&#8221; needed for the healthbot to increase medication adherence.<sup><xref rid="bibr43-20552076231182807" ref-type="bibr">43</xref>,<xref rid="bibr44-20552076231182807" ref-type="bibr">44</xref></sup></p><p>The objective of the study described in this protocol is to co-create a theory-informed, evidence-based, patient-centered healthbot, aimed at helping people adhere to their varenicline regimen, and which healthcare providers (HCPs) feel comfortable recommending. The healthbot developed from this study, once evaluated for its feasibility and effectiveness, may be utilized by patients using varenicline to stop smoking as well as HCPs recommending varenicline, to improve adherence and smoking cessation.</p></sec><sec sec-type="methods" id="section2-20552076231182807"><title>Methods</title><p>We will employ a user-centered approach to build the healthbot in order to optimize user experience and achieve the best uptake and utilization.<sup><xref rid="bibr45-20552076231182807" ref-type="bibr">45</xref>,<xref rid="bibr46-20552076231182807" ref-type="bibr">46</xref></sup> Following the <italic toggle="yes">Discover</italic>, <italic toggle="yes">Design</italic> and <italic toggle="yes">Build</italic>, and <italic toggle="yes">Test</italic> framework,<sup>
<xref rid="bibr47-20552076231182807" ref-type="bibr">47</xref>
</sup> we will use a three-step approach to codesign the core functionality of the healthbot: (a) review the literature and conduct interviews with potential users and HCPs (Discovery phase); (b) design the healthbot and conduct Wizard of Oz testing (Design/Build phase); and (c) train and test the healthbot (Test phase) (<xref rid="fig1-20552076231182807" ref-type="fig">Figure 1</xref>). The Wizard of Oz method is a popular approach wherein research participants interact with a computer system they believe is autonomous; however, responses are actually generated by an unseen human being (the wizard).<sup>
<xref rid="bibr48-20552076231182807" ref-type="bibr">48</xref>
</sup> It is useful in iterative development as it is very easy to change and evolve the wizard's responses. In order to foster a culture of authentic engagement, we will adhere to the guiding principles as laid out in the Strategy for Patient-Oriented Research&#8212;Patient Engagement Framework,<sup>
<xref rid="bibr49-20552076231182807" ref-type="bibr">49</xref>
</sup> including inclusiveness, support, mutual respect, and cobuilding, throughout the co-creation process. We will also be guided by the International Association for Public Participation's Code of Ethics.<sup>
<xref rid="bibr50-20552076231182807" ref-type="bibr">50</xref>
</sup> Approval has been obtained from the Centre for Addiction and Mental Health's (CAMH) Research Ethics Board (REB # 050/2022) and all participants will provide written informed consent before participation.</p><fig position="float" id="fig1-20552076231182807" orientation="portrait"><label>Figure 1.</label><caption><p>Co-creation of a varenicline adherence conversational agent. </p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_20552076231182807-fig1.jpg"/></fig><sec id="section2A-20552076231182807"><title>Discovery phase</title><sec id="section2A1-20552076231182807"><title>Literature review</title><sec id="section2A1A-20552076231182807"><title>Purpose</title><p>The aim of this rapid review is twofold: (a) to identify the barriers and facilitators to varenicline adherence, in people using varenicline for smoking cessation (we will use the Theoretical Domain Framework<sup>
<xref rid="bibr41-20552076231182807" ref-type="bibr">41</xref>
</sup> to organize our data extraction) and (b) to identify the behavior change techniques that are associated with helping people adhere to their varenicline treatment (we will use behavior change technique v1 by Michie et al.<sup>
<xref rid="bibr42-20552076231182807" ref-type="bibr">42</xref>
</sup> to organize our data extraction).</p></sec><sec id="section2A1B-20552076231182807"><title>Methods</title><p>Article inclusion will be based on the population, intervention, comparator, and outcome method for eligibility; the population will be individuals using varenicline for smoking cessation; the intervention will be the use of varenicline; and studies using multiple smoking cessation medications will be included if they reported factors associated with only varenicline users separately. The outcome will be reported factors associated with adherence to varenicline.</p></sec><sec id="section2A1C-20552076231182807"><title>Analysis</title><p>A narrative synthesis of the included studies will be used to summarize the barriers and facilitators to varenicline adherence (using the Theoretical Domain Framework) as well as to identify the behavior change techniques that are associated with helping people adhere to their varenicline treatment.</p></sec></sec><sec id="section2A2-20552076231182807"><title>Semistructured interviews with people who use varenicline</title><sec id="section2A2A-20552076231182807"><title>Purpose</title><p>To gain in-depth understanding of the challenges and solutions people who use varenicline encounter and to understand what features users would like to see in a healthbot designed to help them adhere to varenicline.</p></sec><sec id="section2A2B-20552076231182807"><title>Recruitment</title><p>Recruitment will occur via community boards, CAMH's list of treatment-seeking smokers who consented to being contacted for future studies (the list contains 75,000 contacts), and community agencies partnering with CAMH (such as Rainbow Health Ontario). Interested individuals will contact a team member who will explain the study and assess for inclusion criteria. If eligible, participants will be enrolled in the study.</p></sec><sec id="section2A2C-20552076231182807"><title>Eligibility</title><p>People taking varenicline to quit smoking or self-identifying as nonadherent to their varenicline treatment (i.e. having difficulty taking varenicline as prescribed by their HCP) in the last 6 months, age &#8805;18 years.</p></sec><sec id="section2A2D-20552076231182807"><title>Interviews</title><p>We will interview 20 participants over the phone using a semistructured interview guide, which will probe for common problems taking varenicline and solutions considered appropriate or useful. The interview will follow concepts outlined in the Theoretical Domain Framework<sup>
<xref rid="bibr41-20552076231182807" ref-type="bibr">41</xref>
</sup> and probe for the 11 behavior change techniques that have been identified as possible ways to help people adhere to their medications.<sup>
<xref rid="bibr35-20552076231182807" ref-type="bibr">35</xref>
</sup> Please see attached <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/20552076231182807" ext-link-type="uri">Appendix I</ext-link> for the patient interview guide. The Theoretical Domain Framework provides a framework to examine key determinants (i.e. theoretical domains) of the target behavior (i.e. medication adherence) that can then help identify a specific behavior change intervention.<sup>
<xref rid="bibr51-20552076231182807" ref-type="bibr">51</xref>
</sup> In order to capture a nuanced and comprehensive account of context, we will use the Theoretical Domain Framework with an intersectionality lens.<sup>
<xref rid="bibr52-20552076231182807" ref-type="bibr">52</xref>
</sup> Intersectionality, which accounts for the interface between social identity factors (e.g. age, gender, ethnicity, geography, and class) and structures of power (e.g. racism, ageism, and sexism),<sup><xref rid="bibr53-20552076231182807" ref-type="bibr">53</xref>,<xref rid="bibr54-20552076231182807" ref-type="bibr">54</xref></sup> will offer a novel approach to understand how context shapes the features that should be included in the healthbot. Participants will receive an honorarium in the form of a $30 gift card.</p></sec><sec id="section2A2E-20552076231182807"><title>Analysis</title><p>Interview recordings will be transcribed verbatim and imported into NVivo. We will analyze the data using a framework analysis approach (a type of thematic analysis)<sup>
<xref rid="bibr55-20552076231182807" ref-type="bibr">55</xref>
</sup> which involves a five-step process: (a) familiarization, (b) identifying a thematic framework, (c) indexing, (d) charting, and (e) mapping/interpretation. The analysis will be an ongoing iterative process. Two research staff will review the transcripts to <italic toggle="yes">familiarize</italic> themselves with the data and <italic toggle="yes">identify</italic> initial themes. Although the Theoretical Domain Framework<sup>
<xref rid="bibr51-20552076231182807" ref-type="bibr">51</xref>
</sup> (using an intersectionality lens<sup>
<xref rid="bibr52-20552076231182807" ref-type="bibr">52</xref>
</sup>) has been identified as an a priori framework, additional codes may be identified during the familiarization process to develop a thematic framework. The codes will be <italic toggle="yes">indexed</italic> to sections of the transcripts using NVivo. Any identified themes will be discussed by the two researchers, and coding discrepancies will be resolved through discussion until consensus is reached, followed by further revision of the coding framework. To increase validity and reliability of the study, we will measure the interrater reliability using the kappa coefficient, which is a type of researcher triangulation in which multiple researchers are involved in the analytical process.<sup>
<xref rid="bibr56-20552076231182807" ref-type="bibr">56</xref>
</sup> An audit trail will be used to document our decision-making process. Sections of the transcripts will be <italic toggle="yes">charted</italic> into themes using NVivo. Both coders will review the codes and associated themes multiple times to ensure they reflect participants&#8217; views and to improve the credibility of their <italic toggle="yes">interpretation</italic> of the interviews. In addition, we will draw on contextual data (age, gender, and socioeconomic status) to help us understand the needs of participants from different groups. For example, an older woman from a low socioeconomic status may have different experiences (with varenicline) and needs (with the healthbot) compared to a younger woman from a high socioeconomic status. By considering how age, gender, and socioeconomic status intersect, we will gain a deeper understanding of these differences and will be able to develop a more nuanced healthbot.</p></sec></sec><sec id="section2A3-20552076231182807"><title>Semistructured interviews with healthcare providers who help people who want to quit smoking</title><sec id="section2A3A-20552076231182807"><title>Purpose</title><p>There is currently little guidance regarding HCPs&#8217; perspectives in recommending digital health solutions to their patients; therefore, understanding the perspectives of HCPs is crucial to facilitate the effective delivery and uptake of the healthbot. These semistructured interviews will explore (a) barriers/facilitators influencing HCP provision of digital health solutions to patients prescribed varenicline; (b) identify theoretical domains to target for behavior change; and (c) select behavior change techniques to include in the healthbot.</p></sec><sec id="section2A3B-20552076231182807"><title>Recruitment</title><p>We will recruit 20 HCPs who work with people who are trying to quit smoking including those who work in primary care sites, addiction agencies, and pharmacies. We will also invite HCPs that work at the Nicotine Dependence Clinic at CAMH and in smoking cessation programs in Ontario. A purposive sampling strategy will be used to allow for the inclusion of a variety of sites working in different locations and types of settings.</p></sec><sec id="section2A3C-20552076231182807"><title>Eligibility</title><p>People currently working in a primary care setting, an addiction agency, smoking cessation programs, or registered pharmacy, and as part of their job counsel people who want to quit smoking.</p></sec><sec id="section2A3D-20552076231182807"><title>Interviews</title><p>We will interview 20 participants, over the phone, using a semistructured interview guide, which will probe for barriers and facilitators for implementing/recommending digital health solutions into their care. The interview will follow concepts outlined in the Theoretical Domain Framework.<sup>
<xref rid="bibr41-20552076231182807" ref-type="bibr">41</xref>
</sup> Please see attached <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/20552076231182807" ext-link-type="uri">Appendix II</ext-link> for HCP interview guide.</p></sec><sec id="section2A3E-20552076231182807"><title>Analysis</title><p>Interview recordings will be transcribed verbatim and imported into NVivo and analyzed using framework analysis.<sup>
<xref rid="bibr55-20552076231182807" ref-type="bibr">55</xref>
</sup> The analysis will be an ongoing iterative process. Two research staff will review the transcripts to <italic toggle="yes">familiarize</italic> themselves with the data and <italic toggle="yes">identify</italic> initial themes. Although the Theoretical Domain Framework<sup>
<xref rid="bibr51-20552076231182807" ref-type="bibr">51</xref>
</sup> has been identified as an a priori framework, additional codes may be identified during the familiarization process to develop a thematic framework. The codes will be <italic toggle="yes">indexed</italic> to sections of the transcripts using NVivo. Any identified themes will be discussed by the two researchers, and coding discrepancies will be resolved through discussion until consensus is reached, followed by further revision of the coding framework. To increase validity and reliability of the study, we will measure the interrater reliability, which is a type of researcher triangulation by which multiple researchers are involved in the analytical process.<sup>
<xref rid="bibr56-20552076231182807" ref-type="bibr">56</xref>
</sup> An audit trail will be used to document our decision-making process. Sections of the transcripts will be <italic toggle="yes">charted</italic> into themes using NVivo. Both coders will review the codes and associated themes multiple times to ensure they reflect participants&#8217; views and to improve the credibility of their <italic toggle="yes">interpretation</italic> of the interviews.</p></sec></sec></sec><sec id="section2B-20552076231182807"><title>Design/Build phase</title><sec id="section2B1-20552076231182807"><title>Wizard of Oz method</title><sec id="section2B1A-20552076231182807"><title>Purpose</title><p>The purpose of this stage is to prototype and rapidly evolve the healthbot in an efficient manner.<sup>
<xref rid="bibr48-20552076231182807" ref-type="bibr">48</xref>
</sup> Beginning with structures and responses as suggested by the previous phases, a human-powered wizard will appear as if it is an automated healthbot, allowing the fast evaluation and easy modification of the core components of the healthbot.</p></sec><sec id="section2B1B-20552076231182807"><title>Recruitment</title><p>To ensure that we enroll a diverse group of participants in terms of socioeconomic status, race, gender, age, place of residence, etc., we will use purposeful sampling and recruit through a variety of methods. These will include community boards, CAMH's list of treatment-seeking smokers who consented to being contacted for future studies (list contains 75,000 contacts), community agencies partnering with CAMH, and asking HCPs working in smoking cessation programs to inform their patients. Interested individuals will contact a team member who will explain the study and assess for inclusion criteria. If eligible, participants will be enrolled in the study.</p></sec><sec id="section2B1C-20552076231182807"><title>Eligibility</title><p>Currently taking varenicline to quit smoking or self-identifying as nonadherent to their varenicline treatment in the last 6 months, age &#8805;18 years, and has a smartphone with data plan.</p></sec><sec id="section2B1D-20552076231182807"><title>Procedures</title><p>Forty participants will interact with a healthbot over a smartphone for 10&#8211;30&#8197;minutes per day for 3 days and/or ask 5&#8211;10 questions per day for 3 days. They will be able to send a text (through an existing platform) to the &#8220;healthbot&#8221; (which will be controlled by a research staff member&#8212;the &#8220;wizard&#8221;&#8212;instead of by the actual healthbot). The wizard will be given a library of predefined responses (informed from the interviews and the literature) to provide to participants. Upon user engagement, the wizard will choose an adequate response by clicking on the respective library entry. If none of the listed answers are appropriate for the users&#8217; request or questions, the wizard will reply, &#8220;Sorry, I do not have any information available on this topic; please consult with your healthcare provider. If it is an emergency, please call 911.&#8221; We expect that the initial library of predefined system prompts (derived from the literature and the interviews) will not be sufficient for the various requests; the results of this phase will help us build this library. At the end of their interaction, a research staff will interview participants over the phone. The interviews will be audio recorded and probe for the users&#8217; experiences with the healthbot and suggest any improvements. Participants will receive an honorarium in the form of a $50 gift card.</p></sec><sec id="section2B1E-20552076231182807"><title>Analysis</title><p>The text conversations between participants and the wizard, as well as the audio recordings from the brief interviews, will be imported to NVivo for data management and analysis. We will start by examining all the cases where the wizard had to reply, &#8220;I do not have any information available on this topic,&#8221; the answers that were developed for these questions as well as cases where answers could not be developed, and the evolved library of predefined responses that the healthbot could use. We will then categorize all the questions participants asked the wizard into themes and code keywords that will serve to identify questions the chat should be able to answer. The data will be analyzed using thematic analysis to capture the desired healthbot features.</p></sec><sec id="section2B1F-20552076231182807"><title>Building the healthbot (Build phase)</title><p>Once we have a list of all behavior change techniques identified in the literature and by participants (Discovery and Design phases), the research team will rate them based on whether it is affordable, practical, effective, acceptable, safe, and equitable<sup><xref rid="bibr57-20552076231182807" ref-type="bibr">57</xref>,<xref rid="bibr58-20552076231182807" ref-type="bibr">58</xref></sup> and then decide which behavior change techniques to include in the healthbot. Following guidance from the Nonadoption, Abandonment, Scale-up, Spread, and Sustainability framework,<sup>
<xref rid="bibr59-20552076231182807" ref-type="bibr">59</xref>
</sup> we will build the healthbot choosing the simplest sensible solution for the design. The complexity of healthbots can vary significantly,<sup>
<xref rid="bibr60-20552076231182807" ref-type="bibr">60</xref>
</sup> the simplest are rule-based, meaning they choose responses by searching on keywords and selecting appropriate responses from a predefined library. If users ask questions that do not contain a known keyword, the healthbot will respond with a default message such as, &#8220;Sorry, I did not understand.&#8221;<sup>
<xref rid="bibr61-20552076231182807" ref-type="bibr">61</xref>
</sup> Despite these limitations, simple healthbots are increasingly used.<sup>
<xref rid="bibr61-20552076231182807" ref-type="bibr">61</xref>
</sup> Conversely, complex healthbots use machine learning to determine the meaning of a user's words, which allows them to select an appropriate response to questions. Although the capabilities of such healthbots are rapidly evolving, they do not yet have full human-level language abilities.<sup><xref rid="bibr60-20552076231182807" ref-type="bibr">60</xref>,<xref rid="bibr62-20552076231182807" ref-type="bibr">62</xref></sup> For this study, we will build a rule-based healthbot, which has capabilities to determine the meaning of users&#8217; words. The rules will come from the literature review, the interviews, and Wizard of Oz testing.</p></sec></sec><sec id="section2B2-20552076231182807"><title>Test phase</title><sec id="section2B2A-20552076231182807"><title>Purpose</title><p>Once the healthbot has been co-created with the help of the interviews and Wizard of Oz study, it will be tested to ensure accurate functioning and resolve any errors. The purpose of this phase will be to refine the healthbot with the help of participant feedback, to prepare for future feasibility and effectiveness research.</p></sec><sec id="section2B2B-20552076231182807"><title>Recruitment</title><p>Methods similar to the Wizard of Oz study will be utilized to recruit participants for the testing of the healthbot.</p></sec><sec id="section2B2C-20552076231182807"><title>Eligibility</title><p>People taking varenicline currently to quit smoking or self-identifying as nonadherent to varenicline regimen to quit smoking in the past 6 months, 18 years or older, and have a smartphone with data plan.</p></sec><sec id="section2B2D-20552076231182807"><title>Procedures</title><p>Twenty participants will interact with the healthbot for 1 hour in order to train, beta test, and validate it. After interacting with the healthbot, they will complete a survey providing feedback on the overall experience of using the healthbot and suggest improvements. Participants will receive a $30 gift card as honorarium.</p></sec><sec id="section2B2E-20552076231182807"><title>Analysis</title><p>Chatbot analytics will be examined to capture any glitches in the system (crashes, wrong answers given, etc.). Usage data will be downloaded to understand which questions the chatbot was unable to answer. The follow-up survey will be analyzed using descriptive statistics to explore if any changes to the chatbot are needed.</p></sec></sec></sec></sec><sec sec-type="discussion" id="section3-20552076231182807"><title>Discussion</title><p>Research has shown that offering behavioral supports improves adherence to smoking cessation medications.<sup>
<xref rid="bibr21-20552076231182807" ref-type="bibr">21</xref>
</sup> This study will develop a healthbot as an option to provide these behavioral supports. The healthbot will be built using the latest evidence on barriers and facilitators to varenicline, behavior change theories, and input from end users. By the end of this study, we will have built a healthbot to help people adhere to their varenicline treatment using a systematic, evidence-informed, theory-based approach. Building the healthbot in this way is in line with the UK Medical Research Council complex intervention framework.<sup>
<xref rid="bibr33-20552076231182807" ref-type="bibr">33</xref>
</sup> The results of this study will pave the way for a feasibility evaluation which will then provide clear direction whether to proceed with a randomized controlled trial to examine the effectiveness of the healthbot.</p><sec id="section3A-20552076231182807"><title>Potential challenges and appropriate mitigation strategies</title><p>A common challenge shown in the literature is that the uptake of technology in healthcare is slow<sup><xref rid="bibr63-20552076231182807" ref-type="bibr">63</xref>,<xref rid="bibr64-20552076231182807" ref-type="bibr">64</xref></sup> and there seems to be a gap between the development of technology and usefulness in practice, with many technologies further increasing healthcare complexities.<sup>
<xref rid="bibr65-20552076231182807" ref-type="bibr">65</xref>
</sup> Thus, for this study, we are proposing to use several implementation theories and frameworks to make sure we build from existing knowledge and we can gain insights into the different mechanisms by which implementation of the healthbot is more likely to succeed.</p><p>Given that the provision of digital health can create equity problems (e.g. if the new technology is not accessible to communities that have traditionally been underserved), we are proposing to build the healthbot with social inclusivity in mind. Our plan includes recruiting a diverse group of people (in terms of socioeconomic status, race, age, and gender) and stratifying by age and gender to help with the codesign of the healthbot. In addition, we will build the healthbot to work on operating systems from 2016 or newer, so that most Canadians (80%) can access it.<sup>
<xref rid="bibr66-20552076231182807" ref-type="bibr">66</xref>
</sup> However, 26% of Canadians with incomes of less than $20,000 and 20% those 60 years or older do not own a smartphone<sup>
<xref rid="bibr66-20552076231182807" ref-type="bibr">66</xref>
</sup> and thus will not be able to benefit from this intervention.</p></sec><sec id="section3B-20552076231182807"><title>Expected impact</title><p>Ontario, as much of the world, is experiencing insufficient resources to meet the demand for care, especially given the treatment backlog created by the pandemic. The use of healthbots is a potential partial solution that could increase access to and quality of care and health information in a cost-effective manner. Thus, as demands for digital healthcare strategies increase, this proposed research will advance our knowledge about using healthbots for medication adherence, using an equity lens. In addition, this project has the potential to scale-up to primary care settings, addiction agencies, public health units, and other jurisdictions nationally and internationally to support tobacco control efforts. The intervention can also extend to other medications at a relatively low cost. Finally, because smoking cessation is one of the most important cancer prevention strategies,<sup>
<xref rid="bibr67-20552076231182807" ref-type="bibr">67</xref>
</sup> and with at least one life saved from a tobacco-related death for every two smokers who quit,<sup>
<xref rid="bibr68-20552076231182807" ref-type="bibr">68</xref>
</sup> our research has the potential to impact cancer control and improve quality of life. In Ontario, the national commitment<sup>
<xref rid="bibr69-20552076231182807" ref-type="bibr">69</xref>
</sup> to achieving 5% prevalence of smoking by 2035, strongly endorsed by the Modernization of Smoke-Free Ontario executive steering committee,<sup>
<xref rid="bibr70-20552076231182807" ref-type="bibr">70</xref>
</sup> will require expansion of available cessation services.</p></sec></sec><sec sec-type="conclusions" id="section4-20552076231182807"><title>Conclusions</title><p>To the best of our knowledge, a theory-informed approach has not been utilized to develop a digital health solution to improve adherence to varenicline for smoking cessation. The findings from the study will have the benefit of utilizing a health equity lens to develop a healthbot for behavior change.</p><p>Future research will include a nonrandomized single-arm feasibility study where participants will interact with the co-created healthbot from this study for 12 weeks while taking varenicline for smoking cessation. Based on the findings from the feasibility study, a randomized controlled trial will be conducted to assess the effectiveness of the healthbot.</p></sec><sec sec-type="supplementary-material" specific-use="figshare"><title>Supplemental Material</title><supplementary-material id="supp1-20552076231182807" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-1-dhj-10.1177_20552076231182807 - Supplemental material for Cocreation of a conversational agent to help patients adhere to their varenicline treatment: A study protocol</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-docx-1-dhj-10.1177_20552076231182807.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material, sj-docx-1-dhj-10.1177_20552076231182807 for Cocreation of a conversational agent to help patients adhere to their varenicline treatment: A study protocol by Nadia Minian, Kamna Mehra, Jonathan Rose, Scott Veldhuizen, Laurie Zawertailo, Matt Ratto, Julia Lecce and Peter Selby in DIGITAL HEALTH</p></supplementary-material><supplementary-material id="supp2-20552076231182807" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-2-dhj-10.1177_20552076231182807 - Supplemental material for Cocreation of a conversational agent to help patients adhere to their varenicline treatment: A study protocol</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-docx-2-dhj-10.1177_20552076231182807.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material, sj-docx-2-dhj-10.1177_20552076231182807 for Cocreation of a conversational agent to help patients adhere to their varenicline treatment: A study protocol by Nadia Minian, Kamna Mehra, Jonathan Rose, Scott Veldhuizen, Laurie Zawertailo, Matt Ratto, Julia Lecce and Peter Selby in DIGITAL HEALTH</p></supplementary-material></sec></body><back><fn-group><fn fn-type="other"><p><bold>Contributorship:</bold> NM conceived the study with the support of JR, PS, SV, LZ, and MR. KM was involved in gaining ethical approval. NM wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.</p></fn><fn fn-type="COI-statement"><p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: NM reports receipt of funding from Canadian Institutes of Health Research, Canadian Cancer Society, and from the Discovery Fund of CAMH. PS reports receipt of funding from Canadian Institutes of Health Research, Canadian Cancer Society, Pfizer Inc., Pfizer Canada, and Ontario Lung Association. PS also reports that through an open tender process, Johnson &amp; Johnson, Novartis, and Pfizer Inc. are vendors of record for having provided smoking cessation pharmacotherapy for research studies at free or discounted rates.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research is funded by a Proof of Concept Intervention Grant in Primary Prevention of Cancer (Action Grant) of the Canadian Cancer Society and the Canadian Institutes of Health Research-Institute for Cancer Research (grant #707218) and a Canadian Institutes of Health Research Project Grant: Funding Reference Number: PJT 180405.</p></fn><fn fn-type="other"><p><bold>Ethical approval:</bold> The Research Ethics Board of the Centre for Addiction and Mental Health approved this study (REB number: 50/2022).</p></fn><fn fn-type="other"><p><bold>Guarantor:</bold> NM</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Nadia Minian <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-8179-3628" ext-link-type="uri">https://orcid.org/0000-0001-8179-3628</ext-link></p></fn><fn fn-type="other"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-20552076231182807"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maciosek</surname><given-names>MV</given-names></name><name name-style="western"><surname>Coffield</surname><given-names>AB</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>NM</given-names></name></person-group>, <etal>et al.</etal><article-title>Priorities among effective clinical preventive services: results of a systematic review and analysis</article-title>. <source>Am J Prev Med</source><year>2006</year>; <volume>31</volume>: <fpage>52</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">16777543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2006.03.012</pub-id></mixed-citation></ref><ref id="bibr2-20552076231182807"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solberg</surname><given-names>LI</given-names></name><name name-style="western"><surname>Maciosek</surname><given-names>MV</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>NM</given-names></name></person-group>, <etal>et al.</etal><article-title>Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness</article-title>. <source>Am J Prev Med</source><year>2006</year>; <volume>31</volume>: <fpage>62</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">16777544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2006.03.013</pub-id></mixed-citation></ref><ref id="bibr3-20552076231182807"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cahill</surname><given-names>K</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>S</given-names></name><name name-style="western"><surname>Perera</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Pharmacological interventions for smoking cessation: an overview and network meta-analysis</article-title>. <source>Cochrane Database Syst Rev</source><year>2013</year>: <fpage>CD009329</fpage>. <comment>20130531</comment>. DOI: <pub-id pub-id-type="doi">10.1002/14651858.CD009329.pub2.</pub-id><pub-id pub-id-type="pmid">23728690</pub-id><pub-id pub-id-type="pmcid">PMC8406789</pub-id></mixed-citation></ref><ref id="bibr4-20552076231182807"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perkins</surname><given-names>KA</given-names></name><name name-style="western"><surname>Scott</surname><given-names>J</given-names></name></person-group>. <article-title>Sex differences in long-term smoking cessation rates due to nicotine patch</article-title>. <source>Nicotine Tob Res</source><year>2008</year>; <volume>10</volume>: <fpage>1245</fpage>&#8211;<lpage>1250</lpage>.<pub-id pub-id-type="pmid">18629735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14622200802097506</pub-id></mixed-citation></ref><ref id="bibr5-20552076231182807"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinberger</surname><given-names>AH</given-names></name><name name-style="western"><surname>Smith</surname><given-names>PH</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Consideration of sex in clinical trials of transdermal nicotine patch: a systematic review</article-title>. <source>Exp Clin Psychopharmacol</source><year>2014</year>; <volume>22</volume>: <fpage>373</fpage>&#8211;<lpage>383</lpage>. <comment>20140818</comment>.<pub-id pub-id-type="pmid">25133506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/a0037692</pub-id><pub-id pub-id-type="pmcid">PMC4180800</pub-id></mixed-citation></ref><ref id="bibr6-20552076231182807"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKee</surname><given-names>SA</given-names></name><name name-style="western"><surname>Smith</surname><given-names>PH</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Sex differences in varenicline efficacy for smoking cessation: a meta-analysis</article-title>. <source>Nicotine Tob Res</source><year>2016</year>; <volume>18</volume>: <fpage>1002</fpage>&#8211;<lpage>1011</lpage>. <comment>20151006</comment>.<pub-id pub-id-type="pmid">26446070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ntr/ntv207</pub-id><pub-id pub-id-type="pmcid">PMC5942618</pub-id></mixed-citation></ref><ref id="bibr7-20552076231182807"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>K</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>S</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>SC</given-names></name></person-group>. <article-title>Varenicline for smoking cessation: a review of the literature</article-title>. <source>Curr Ther Res Clin Exp</source><year>2009</year>; <volume>70</volume>: <fpage>35</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">24692831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.curtheres.2009.02.004</pub-id><pub-id pub-id-type="pmcid">PMC3969980</pub-id></mixed-citation></ref><ref id="bibr8-20552076231182807"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacek</surname><given-names>LR</given-names></name><name name-style="western"><surname>McClernon</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Bosworth</surname><given-names>HB</given-names></name></person-group>. <article-title>Adherence to pharmacological smoking cessation interventions: a literature review and synthesis of correlates and barriers</article-title>. <source>Nicotine Tob Res</source><year>2018</year>; <volume>20</volume>: <fpage>1163</fpage>&#8211;<lpage>1172</lpage>. <comment>2017/10/24</comment>.<pub-id pub-id-type="pmid">29059394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ntr/ntx210</pub-id><pub-id pub-id-type="pmcid">PMC6121917</pub-id></mixed-citation></ref><ref id="bibr9-20552076231182807"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liberman</surname><given-names>JN</given-names></name><name name-style="western"><surname>Lichtenfeld</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Galaznik</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Adherence to varenicline and associated smoking cessation in a community-based patient setting</article-title>. <source>J Manag Care Pharm</source><year>2013</year>; <volume>19</volume>: <fpage>125</fpage>&#8211;<lpage>131</lpage>.<pub-id pub-id-type="pmid">23461428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18553/jmcp.2013.19.2.125</pub-id><pub-id pub-id-type="pmcid">PMC10437765</pub-id></mixed-citation></ref><ref id="bibr10-20552076231182807"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Killen</surname><given-names>JD</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>TN</given-names></name><name name-style="western"><surname>Ammerman</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers</article-title>. <source>J Consult Clin Psychol</source><year>2004</year>; <volume>72</volume>: <fpage>729</fpage>&#8211;<lpage>735</lpage>.<pub-id pub-id-type="pmid">15301658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/0022-006X.72.4.729</pub-id></mixed-citation></ref><ref id="bibr11-20552076231182807"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitz</surname><given-names>JM</given-names></name><name name-style="western"><surname>Stotts</surname><given-names>AL</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>ME</given-names></name></person-group>, <etal>et al.</etal><article-title>Bupropion and cognitive-behavioral therapy for smoking cessation in women</article-title>. <source>Nicotine Tob Res</source><year>2007</year>; <volume>9</volume>: <fpage>699</fpage>&#8211;<lpage>709</lpage>.<pub-id pub-id-type="pmid">17558827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14622200701365335</pub-id></mixed-citation></ref><ref id="bibr12-20552076231182807"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catz</surname><given-names>SL</given-names></name><name name-style="western"><surname>Jack</surname><given-names>LM</given-names></name><name name-style="western"><surname>McClure</surname><given-names>JB</given-names></name></person-group>, <etal>et al.</etal><article-title>Adherence to varenicline in the COMPASS smoking cessation intervention trial</article-title>. <source>Nicotine Tob Res</source><year>2011</year>; <volume>13</volume>: <fpage>361</fpage>&#8211;<lpage>368</lpage>. <comment>20110224</comment>.<pub-id pub-id-type="pmid">21350041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ntr/ntr003</pub-id><pub-id pub-id-type="pmcid">PMC3082504</pub-id></mixed-citation></ref><ref id="bibr13-20552076231182807"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Jones</surname><given-names>PG</given-names></name><name name-style="western"><surname>Bybee</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>A longer course of varenicline therapy improves smoking cessation rates</article-title>. <source>Prev Cardiol</source><year>2008</year>; <volume>11</volume>: <fpage>210</fpage>&#8211;<lpage>214</lpage>.<pub-id pub-id-type="pmid">19476573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1751-7141.2008.00003.x</pub-id></mixed-citation></ref><ref id="bibr14-20552076231182807"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>AR</given-names></name><name name-style="western"><surname>Morales</surname><given-names>M</given-names></name><name name-style="western"><surname>Wileyto</surname><given-names>EP</given-names></name></person-group>, <etal>et al.</etal><article-title>Measures and predictors of varenicline adherence in the treatment of nicotine dependence</article-title>. <source>Addict Behav</source><year>2017</year>; <volume>75</volume>: <fpage>122</fpage>&#8211;<lpage>129</lpage>. <comment>2017/07/21</comment>.<pub-id pub-id-type="pmid">28728040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addbeh.2017.07.006</pub-id><pub-id pub-id-type="pmcid">PMC5581992</pub-id></mixed-citation></ref><ref id="bibr15-20552076231182807"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>AR</given-names></name><name name-style="western"><surname>Schnoll</surname><given-names>R</given-names></name><name name-style="western"><surname>Hawk</surname><given-names>LW</given-names><suffix>Jr.</suffix></name></person-group>, <etal>et al.</etal><article-title>Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: impact on pharmacogenetic trial outcomes</article-title>. <source>Drug Alcohol Depend</source><year>2018</year>; <volume>190</volume>: <fpage>72</fpage>&#8211;<lpage>81</lpage>. <comment>20180626</comment>.<pub-id pub-id-type="pmid">29986268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2018.04.035</pub-id><pub-id pub-id-type="pmcid">PMC6085881</pub-id></mixed-citation></ref><ref id="bibr16-20552076231182807"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>AR</given-names></name><name name-style="western"><surname>Swardfager</surname><given-names>W</given-names></name><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name></person-group>, <etal>et al.</etal><article-title>Impact of early nausea on varenicline adherence and smoking cessation</article-title>. <source>Addiction</source><year>2020</year>; <volume>115</volume>: <fpage>134</fpage>&#8211;<lpage>144</lpage>. <comment>20191105</comment>.<pub-id pub-id-type="pmid">31502736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.14810</pub-id><pub-id pub-id-type="pmcid">PMC6933078</pub-id></mixed-citation></ref><ref id="bibr17-20552076231182807"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solberg</surname><given-names>LI</given-names></name><name name-style="western"><surname>Parker</surname><given-names>ED</given-names></name><name name-style="western"><surname>Foldes</surname><given-names>SS</given-names></name></person-group>, <etal>et al.</etal><article-title>Disparities in tobacco cessation medication orders and fills among special populations</article-title>. <source>Nicotine Tob Res</source><year>2010</year>; <volume>12</volume>: <fpage>144</fpage>&#8211;<lpage>151</lpage>. <comment>20091217</comment>.<pub-id pub-id-type="pmid">20018945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ntr/ntp187</pub-id></mixed-citation></ref><ref id="bibr18-20552076231182807"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CI</given-names></name><name name-style="western"><surname>Mastey</surname><given-names>V</given-names></name></person-group>, <etal>et al.</etal><article-title>Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims</article-title>. <source>Clin Ther</source><year>2011</year>; <volume>33</volume>: <fpage>225</fpage>&#8211;<lpage>234</lpage>.<pub-id pub-id-type="pmid">21497706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2011.02.013</pub-id></mixed-citation></ref><ref id="bibr19-20552076231182807"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>TV</given-names></name><name name-style="western"><surname>DeBon</surname><given-names>MW</given-names></name><name name-style="western"><surname>Stockton</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Correlates of adherence with transdermal nicotine</article-title>. <source>Addict Behav</source><year>2004</year>; <volume>29</volume>: <fpage>1565</fpage>&#8211;<lpage>1578</lpage>.<pub-id pub-id-type="pmid">15451124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addbeh.2004.02.033</pub-id></mixed-citation></ref><ref id="bibr20-20552076231182807"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voci</surname><given-names>SC</given-names></name><name name-style="western"><surname>Zawertailo</surname><given-names>LA</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Association between adherence to free nicotine replacement therapy and successful quitting</article-title>. <source>Addict Behav</source><year>2016</year>; <volume>61</volume>: <fpage>25</fpage>&#8211;<lpage>31</lpage>. <comment>20160513</comment>.<pub-id pub-id-type="pmid">27235989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addbeh.2016.05.012</pub-id></mixed-citation></ref><ref id="bibr21-20552076231182807"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hollands</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Naughton</surname><given-names>F</given-names></name><name name-style="western"><surname>Farley</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Interventions to increase adherence to medications for tobacco dependence</article-title>. <source>Cochrane Database Syst Rev</source><year>2019</year>; <volume>8</volume>: <fpage>Cd009164</fpage>. <comment>2019/08/20</comment>.<pub-id pub-id-type="pmid">31425618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD009164.pub3</pub-id><pub-id pub-id-type="pmcid">PMC6699660</pub-id></mixed-citation></ref><ref id="bibr22-20552076231182807"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conn</surname><given-names>VS</given-names></name><name name-style="western"><surname>Ruppar</surname><given-names>TM</given-names></name></person-group>. <article-title>Medication adherence outcomes of 771 intervention trials: systematic review and meta-analysis</article-title>. <source>Prev Med</source><year>2017</year>; <volume>99</volume>: <fpage>269</fpage>&#8211;<lpage>276</lpage>. <comment>2017/03/21</comment>.<pub-id pub-id-type="pmid">28315760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ypmed.2017.03.008</pub-id><pub-id pub-id-type="pmcid">PMC5467216</pub-id></mixed-citation></ref><ref id="bibr23-20552076231182807"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olano-Espinosa</surname><given-names>E</given-names></name><name name-style="western"><surname>Avila-Tomas</surname><given-names>JF</given-names></name><name name-style="western"><surname>Minue-Lorenzo</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Effectiveness of a conversational Chatbot (Dejal@ bot) for the adult population to quit smoking: pragmatic, multicenter, controlled, randomized clinical trial in primary care</article-title>. <source>JMIR Mhealth Uhealth</source><year>2022</year>; <volume>10</volume>: <fpage>e34273</fpage>.<pub-id pub-id-type="pmid">35759328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/34273</pub-id><pub-id pub-id-type="pmcid">PMC9274388</pub-id></mixed-citation></ref><ref id="bibr24-20552076231182807"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavel</surname><given-names>M</given-names></name><name name-style="western"><surname>Jimison</surname><given-names>HB</given-names></name><name name-style="western"><surname>Wactlar</surname><given-names>HD</given-names></name></person-group>, <etal>et al.</etal><article-title>The role of technology and engineering models in transforming healthcare</article-title>. <source>IEEE Rev Biomed Eng</source><year>2013</year>; <volume>6</volume>: <fpage>156</fpage>&#8211;<lpage>177</lpage>.<pub-id pub-id-type="pmid">23549108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/RBME.2012.2222636</pub-id></mixed-citation></ref><ref id="bibr25-20552076231182807"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rathbone</surname><given-names>AL</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>J</given-names></name></person-group>. <article-title>The use of mobile apps and SMS messaging as physical and mental health interventions: systematic review</article-title>. <source>J Med Internet Res</source><year>2017</year>; <volume>19</volume>: <fpage>e295</fpage>. <comment>2017/08/26</comment>.<pub-id pub-id-type="pmid">28838887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/jmir.7740</pub-id><pub-id pub-id-type="pmcid">PMC5590007</pub-id></mixed-citation></ref><ref id="bibr26-20552076231182807"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>M</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>R</given-names></name><name name-style="western"><surname>Haines</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Framework for design and evaluation of complex interventions to improve health</article-title>. <source>Br Med J</source><year>2000</year>; <volume>321</volume>: <fpage>694</fpage>&#8211;<lpage>696</lpage>. <comment>2000/09/15</comment>.<pub-id pub-id-type="pmid">10987780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.321.7262.694</pub-id><pub-id pub-id-type="pmcid">PMC1118564</pub-id></mixed-citation></ref><ref id="bibr27-20552076231182807"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McClure</surname><given-names>JB</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Evaluating an adaptive and interactive mHealth smoking cessation and medication adherence program: a randomized pilot feasibility study</article-title>. <source>JMIR Mhealth Uhealth</source><year>2016</year>; <volume>4</volume>: <fpage>e6002</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/mhealth.6002</pub-id><pub-id pub-id-type="pmcid">PMC4989120</pub-id><pub-id pub-id-type="pmid">27489247</pub-id></mixed-citation></ref><ref id="bibr28-20552076231182807"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>JS</given-names></name><name name-style="western"><surname>Armin</surname><given-names>JS</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>JK</given-names></name></person-group>, <etal>et al.</etal><article-title>Lessons learned in the development and evaluation of RxCoach&#8482;, an mHealth app to increase tobacco cessation medication adherence</article-title>. <source>Patient Educ Couns</source><year>2017</year>; <volume>100</volume>: <fpage>720</fpage>&#8211;<lpage>727</lpage>.<pub-id pub-id-type="pmid">27839891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pec.2016.11.003</pub-id><pub-id pub-id-type="pmcid">PMC5385274</pub-id></mixed-citation></ref><ref id="bibr29-20552076231182807"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruno</surname><given-names>M</given-names></name><name name-style="western"><surname>Wright</surname><given-names>M</given-names></name><name name-style="western"><surname>Baker</surname><given-names>CL</given-names></name></person-group>, <etal>et al.</etal><article-title>Mobile app usage patterns of patients prescribed a smoking cessation medicine: prospective observational study</article-title>. <source>JMIR Mhealth Uhealth</source><year>2018</year>; <volume>6</volume>: <fpage>e9115</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/mhealth.9115</pub-id><pub-id pub-id-type="pmcid">PMC5930175</pub-id><pub-id pub-id-type="pmid">29666043</pub-id></mixed-citation></ref><ref id="bibr30-20552076231182807"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>HY</given-names></name><name name-style="western"><surname>Yu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>QH</given-names></name></person-group>, <etal>et al.</etal><article-title>Tailored interventions to improve medication adherence for cardiovascular diseases</article-title>. <source>Front Pharmacol</source><year>2020</year>; <volume>11</volume>: <fpage>510339</fpage>. <comment>2020/12/29</comment>.<pub-id pub-id-type="pmid">33364935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.510339</pub-id><pub-id pub-id-type="pmcid">PMC7751638</pub-id></mixed-citation></ref><ref id="bibr31-20552076231182807"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parmar</surname><given-names>P</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J</given-names></name><name name-style="western"><surname>Pandya</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Health-focused conversational agents in person-centered care: a review of apps</article-title>. <source>npj Digital Medicine</source><year>2022</year>; <volume>5</volume>: <fpage>21</fpage>.<pub-id pub-id-type="pmid">35177772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-022-00560-6</pub-id><pub-id pub-id-type="pmcid">PMC8854396</pub-id></mixed-citation></ref><ref id="bibr32-20552076231182807"><label>32</label><mixed-citation publication-type="book"><part-title>The Morgan Kaufmann series in interactive technologies</part-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Courage</surname><given-names>C</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>K</given-names></name></person-group> (eds) <source>Understanding your users</source>. <publisher-loc>San Francisco</publisher-loc>: <publisher-name>Morgan Kaufmann</publisher-name>, <year>2005</year>, pp.<fpage>iv</fpage>.</mixed-citation></ref><ref id="bibr33-20552076231182807"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skivington</surname><given-names>K</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>L</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>SA</given-names></name></person-group>, <etal>et al.</etal><article-title>A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance</article-title>. <source>Br Med J</source><year>2021</year>; <volume>374</volume>: <fpage>n2061</fpage>.<pub-id pub-id-type="pmid">34593508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n2061</pub-id><pub-id pub-id-type="pmcid">PMC8482308</pub-id></mixed-citation></ref><ref id="bibr34-20552076231182807"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craig</surname><given-names>P</given-names></name><name name-style="western"><surname>Dieppe</surname><given-names>P</given-names></name><name name-style="western"><surname>Macintyre</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Developing and evaluating complex interventions: the new Medical Research Council guidance</article-title>. <source>Br Med J</source><year>2008</year>; <volume>337</volume>: <fpage>a1655</fpage>.<pub-id pub-id-type="pmid">18824488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.a1655</pub-id><pub-id pub-id-type="pmcid">PMC2769032</pub-id></mixed-citation></ref><ref id="bibr35-20552076231182807"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patton</surname><given-names>DE</given-names></name><name name-style="western"><surname>Cadogan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Improving adherence to multiple medications in older people in primary care: selecting intervention components to address patient-reported barriers and facilitators</article-title>. <source>Health Expect</source><year>2018</year>; <volume>21</volume>: <fpage>138</fpage>&#8211;<lpage>148</lpage>. <comment>2017/08/03</comment>.<pub-id pub-id-type="pmid">28766816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/hex.12595</pub-id><pub-id pub-id-type="pmcid">PMC5750691</pub-id></mixed-citation></ref><ref id="bibr36-20552076231182807"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieuwlaat</surname><given-names>R</given-names></name><name name-style="western"><surname>Wilczynski</surname><given-names>N</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Interventions for enhancing medication adherence</article-title>. <source>Cochrane Database Syst Rev</source><year>2014</year>; <volume>2014</volume>: <fpage>Cd000011</fpage>. <comment>2014/11/21</comment>.<pub-id pub-id-type="pmid">25412402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD000011.pub4</pub-id><pub-id pub-id-type="pmcid">PMC7263418</pub-id></mixed-citation></ref><ref id="bibr37-20552076231182807"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patton</surname><given-names>DE</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>CM</given-names></name><name name-style="western"><surname>Cadogan</surname><given-names>CA</given-names></name></person-group>, <etal>et al.</etal><article-title>Theory-based interventions to improve medication adherence in older adults prescribed polypharmacy: a systematic review</article-title>. <source>Drug Aging</source><year>2017</year>; <volume>34</volume>: <fpage>97</fpage>&#8211;<lpage>113</lpage>. <comment>2016/12/28</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40266-016-0426-6</pub-id><pub-id pub-id-type="pmcid">PMC5290062</pub-id><pub-id pub-id-type="pmid">28025725</pub-id></mixed-citation></ref><ref id="bibr38-20552076231182807"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Bruin</surname><given-names>M</given-names></name><name name-style="western"><surname>Black</surname><given-names>N</given-names></name><name name-style="western"><surname>Javornik</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Underreporting of the active content of behavioural interventions: a systematic review and meta-analysis of randomised trials of smoking cessation interventions</article-title>. <source>Health Psychol Rev</source><year>2021</year>; <volume>15</volume>: <fpage>195</fpage>&#8211;<lpage>213</lpage>. <comment>2020/01/08</comment>.<pub-id pub-id-type="pmid">31906781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17437199.2019.1709098</pub-id></mixed-citation></ref><ref id="bibr39-20552076231182807"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyon</surname><given-names>AR</given-names></name><name name-style="western"><surname>Munson</surname><given-names>SA</given-names></name><name name-style="western"><surname>Renn</surname><given-names>BN</given-names></name></person-group>, <etal>et al.</etal><article-title>Use of human-centered design to improve implementation of evidence-based psychotherapies in low-resource communities: protocol for studies applying a framework to assess usability</article-title>. <source>JMIR Res Protoc</source><year>2019</year>; <volume>8</volume>: <fpage>e14990</fpage>. <comment>20191009</comment>.<pub-id pub-id-type="pmid">31599736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/14990</pub-id><pub-id pub-id-type="pmcid">PMC6819011</pub-id></mixed-citation></ref><ref id="bibr40-20552076231182807"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michie</surname><given-names>S</given-names></name><name name-style="western"><surname>van Stralen</surname><given-names>M</given-names></name><name name-style="western"><surname>West</surname><given-names>R</given-names></name></person-group>. <article-title>The behaviour change wheel: a new method for characterising and designing behaviour change interventions</article-title>. <source>Implement Sci</source><year>2011</year>; <volume>6</volume>. doi:<pub-id pub-id-type="doi">10.1186/1748-5908-1186-1142</pub-id><pub-id pub-id-type="pmcid">PMC3096582</pub-id><pub-id pub-id-type="pmid">21513547</pub-id></mixed-citation></ref><ref id="bibr41-20552076231182807"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cane</surname><given-names>J</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>D</given-names></name><name name-style="western"><surname>Michie</surname><given-names>S</given-names></name></person-group>. <article-title>Validation of the theoretical domains framework for use in behaviour change and implementation research</article-title>. <source>Implementation Science : IS</source><year>2012</year>; <volume>7</volume>: <fpage>37</fpage>. <comment>20120424</comment>.<pub-id pub-id-type="pmid">22530986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1748-5908-7-37</pub-id><pub-id pub-id-type="pmcid">PMC3483008</pub-id></mixed-citation></ref><ref id="bibr42-20552076231182807"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michie</surname><given-names>S</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions</article-title>. <source>Ann Behav Med</source><year>2013</year>; <volume>46</volume>: <fpage>81</fpage>&#8211;<lpage>95</lpage>. <comment>2013/03/21</comment>.<pub-id pub-id-type="pmid">23512568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12160-013-9486-6</pub-id></mixed-citation></ref><ref id="bibr43-20552076231182807"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>C</given-names></name><name name-style="western"><surname>Eliasson</surname><given-names>&#194;L</given-names></name><name name-style="western"><surname>Barber</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Applying COM-B to medication adherence: a suggested framework for research and interventions</article-title>. <source>Eur Health Psychol</source><year>2014</year>; <volume>16</volume>: <fpage>7</fpage>&#8211;<lpage>17</lpage>.</mixed-citation></ref><ref id="bibr44-20552076231182807"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrissey</surname><given-names>EC</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>TK</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>JC</given-names></name></person-group>, <etal>et al.</etal><article-title>Behavior change techniques in apps for medication adherence: a content analysis</article-title>. <source>Am J Prev Med</source><year>2016</year>; <volume>50</volume>: <fpage>e143</fpage>&#8211;<lpage>e146</lpage>.<pub-id pub-id-type="pmid">26597504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2015.09.034</pub-id></mixed-citation></ref><ref id="bibr45-20552076231182807"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nadarzynski</surname><given-names>T</given-names></name><name name-style="western"><surname>Miles</surname><given-names>O</given-names></name><name name-style="western"><surname>Cowie</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Acceptability of artificial intelligence (AI)-led chatbot services in healthcare: a mixed-methods study</article-title>. <source>Digit Health</source><year>2019</year>; <volume>5</volume>: <fpage>2055207619871808</fpage>. <comment>20190821</comment>.<pub-id pub-id-type="pmid">31467682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2055207619871808</pub-id><pub-id pub-id-type="pmcid">PMC6704417</pub-id></mixed-citation></ref><ref id="bibr46-20552076231182807"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yardley</surname><given-names>L</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>L</given-names></name><name name-style="western"><surname>Bradbury</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>The person-based approach to intervention development: application to digital health-related behavior change interventions</article-title>. <source>J Med Internet Res</source><year>2015</year>; <volume>17</volume>: <fpage>e30</fpage>. <comment>20150130</comment>.<pub-id pub-id-type="pmid">25639757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/jmir.4055</pub-id><pub-id pub-id-type="pmcid">PMC4327440</pub-id></mixed-citation></ref><ref id="bibr47-20552076231182807"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyon</surname><given-names>AR</given-names></name><name name-style="western"><surname>Munson</surname><given-names>SA</given-names></name><name name-style="western"><surname>Renn</surname><given-names>BN</given-names></name></person-group>, <etal>et al.</etal><article-title>Use of human-centered design to improve implementation of evidence-based psychotherapies in low-resource communities: protocol for studies applying a framework to assess usability</article-title>. <source>JMIR Res Protoc</source><year>2019</year>; <volume>8</volume>: <fpage>e14990</fpage>. <comment>2019/10/11</comment>.<pub-id pub-id-type="pmid">31599736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/14990</pub-id><pub-id pub-id-type="pmcid">PMC6819011</pub-id></mixed-citation></ref><ref id="bibr48-20552076231182807"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelley</surname><given-names>JF</given-names></name></person-group>. <article-title>An iterative design methodology for user-friendly natural language office information applications</article-title>. <source>ACM Trans Inf Syst</source><year>1984</year>; <volume>2</volume>: <fpage>26</fpage>&#8211;<lpage>41</lpage>. DOI: <pub-id pub-id-type="doi">10.1145/357417.357420</pub-id>.</mixed-citation></ref><ref id="bibr49-20552076231182807"><label>49</label><mixed-citation publication-type="book"><collab>CIHR</collab>. <source>Strategy for patient-oriented research patient engagement framework</source>. <publisher-loc>Canada</publisher-loc>: <publisher-name>CIHR</publisher-name>, <year>2014</year>.</mixed-citation></ref><ref id="bibr50-20552076231182807"><label>50</label><mixed-citation publication-type="other"><collab>International Association of Public Participation (IAP2)</collab>. <comment>International Association for Public Participation&#8217;s Code of Ethics</comment>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.iap2.org/page/ethics" ext-link-type="uri">https://www.iap2.org/page/ethics</ext-link> (<comment>accessed March 17 2021 2021</comment>).</mixed-citation></ref><ref id="bibr51-20552076231182807"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michie</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>M</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Making psychological theory useful for implementing evidence based practice: a consensus approach</article-title>. <source>Qual Saf Health Care</source><year>2005</year>; <volume>14</volume>: <fpage>26</fpage>&#8211;<lpage>33</lpage>. <comment>2005/02/05</comment>.<pub-id pub-id-type="pmid">15692000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/qshc.2004.011155</pub-id><pub-id pub-id-type="pmcid">PMC1743963</pub-id></mixed-citation></ref><ref id="bibr52-20552076231182807"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Etherington</surname><given-names>N</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>IB</given-names></name><name name-style="western"><surname>Giangregorio</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Applying an intersectionality lens to the theoretical domains framework: a tool for thinking about how intersecting social identities and structures of power influence behaviour</article-title>. <source>BMC Med Res Methodol</source><year>2020</year>; <volume>20</volume>: <fpage>169</fpage>.<pub-id pub-id-type="pmid">32590940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12874-020-01056-1</pub-id><pub-id pub-id-type="pmcid">PMC7318508</pub-id></mixed-citation></ref><ref id="bibr53-20552076231182807"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCall</surname><given-names>L</given-names></name></person-group>. <article-title>The complexity of intersectionality</article-title>. <source>J Women Cult Soc</source><year>2005</year>; <volume>30</volume>: <fpage>1771</fpage>&#8211;<lpage>1800</lpage>.</mixed-citation></ref><ref id="bibr54-20552076231182807"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crenshaw</surname><given-names>K</given-names></name></person-group>. <article-title>Mapping the margins: intersectionality, identity politics, and violence against women of color</article-title>. <source>Stanford Law Rev</source><year>1993</year>; <volume>43</volume>: <fpage>1241</fpage>&#8211;<lpage>1299</lpage>.</mixed-citation></ref><ref id="bibr55-20552076231182807"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gale</surname><given-names>NK</given-names></name><name name-style="western"><surname>Heath</surname><given-names>G</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>Using the framework method for the analysis of qualitative data in multi-disciplinary health research</article-title>. <source>BMC Med Res Methodol</source><year>2013</year>; <volume>13</volume>: <fpage>117</fpage>. <comment>2013/09/21</comment>.<pub-id pub-id-type="pmid">24047204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2288-13-117</pub-id><pub-id pub-id-type="pmcid">PMC3848812</pub-id></mixed-citation></ref><ref id="bibr56-20552076231182807"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitto</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chesters</surname><given-names>J</given-names></name><name name-style="western"><surname>Grbich</surname><given-names>C</given-names></name></person-group>. <article-title>Quality in qualitative research</article-title>. <source>Med J Aust</source><year>2008</year>; <volume>188</volume>: <fpage>243</fpage>&#8211;<lpage>246</lpage>.<pub-id pub-id-type="pmid">18279135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5694/j.1326-5377.2008.tb01595.x</pub-id></mixed-citation></ref><ref id="bibr57-20552076231182807"><label>57</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Michie</surname><given-names>S</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>L</given-names></name><name name-style="western"><surname>West</surname><given-names>R</given-names></name></person-group>. <source>The behaviour change wheel. A guide to designing interventions 1st ed</source>. <publisher-loc>Great Britain</publisher-loc>: <publisher-name>Silverback Publishing</publisher-name>, <year>2014</year>: <fpage>1003</fpage>&#8211;<lpage>1010</lpage>.</mixed-citation></ref><ref id="bibr58-20552076231182807"><label>58</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Michie</surname><given-names>S</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>L</given-names></name><name name-style="western"><surname>West</surname><given-names>R</given-names></name></person-group>. <source>The behaviour change wheel: a guide to designing interventions. 2014</source>. <publisher-loc>Great Britain</publisher-loc>: <publisher-name>Silverback Publishing</publisher-name>, <year>2015</year>.</mixed-citation></ref><ref id="bibr59-20552076231182807"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abimbola</surname><given-names>S</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>The NASSS framework for ex post theorisation of technology-supported change in healthcare: worked example of the TORPEDO programme</article-title>. <source>BMC Med</source><year>2019</year>; <volume>17</volume>: <fpage>233</fpage>. <comment>20191230</comment>.<pub-id pub-id-type="pmid">31888718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-019-1463-x</pub-id><pub-id pub-id-type="pmcid">PMC6937726</pub-id></mixed-citation></ref><ref id="bibr60-20552076231182807"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Car</surname><given-names>T</given-names></name><name name-style="western"><surname>Dhinagaran</surname><given-names>L</given-names></name><name name-style="western"><surname>Kyaw</surname><given-names>DA</given-names></name></person-group>, <etal>et al.</etal><article-title>Conversational agents in health care: scoping review and conceptual analysis</article-title>. <source>J Med Internet Res</source><year>2020</year>; <volume>22</volume>: <fpage>e17158</fpage>&#8211;<lpage>20200807</lpage>.<pub-id pub-id-type="pmid">32763886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/17158</pub-id><pub-id pub-id-type="pmcid">PMC7442948</pub-id></mixed-citation></ref><ref id="bibr61-20552076231182807"><label>61</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Veretskaya</surname><given-names>O</given-names></name></person-group>. <comment>What is a chatbot and how to use it for your business</comment>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://medium.com/swlh/what-is-a-chatbot-and-how-to-use-it-for-your-business-976ec2e0a99f" ext-link-type="uri">https://medium.com/swlh/what-is-a-chatbot-and-how-to-use-it-for-your-business-976ec2e0a99f</ext-link> (<year>2017</year>, <comment>accessed Oct 2 2020 2020</comment>).</mixed-citation></ref><ref id="bibr62-20552076231182807"><label>62</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Platform</surname><given-names>O-SCA</given-names></name></person-group>. <comment>What is a chatbot? All you need to know about chatbots!. Botpress</comment>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://botpress.io/learn/what-and-why/" ext-link-type="uri">https://botpress.io/learn/what-and-why/</ext-link> (<year>2018</year>, <comment>accessed Oct 2, 2020 2020</comment>).</mixed-citation></ref><ref id="bibr63-20552076231182807"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Limburg</surname><given-names>M</given-names></name><name name-style="western"><surname>van Gemert-Pijnen</surname><given-names>JE</given-names></name><name name-style="western"><surname>Nijland</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Why business modeling is crucial in the development of eHealth technologies</article-title>. <source>J Med Internet Res</source><year>2011</year>; <volume>13</volume>: <fpage>e124</fpage>. <comment>20111228</comment>.<pub-id pub-id-type="pmid">22204896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/jmir.1674</pub-id><pub-id pub-id-type="pmcid">PMC3278110</pub-id></mixed-citation></ref><ref id="bibr64-20552076231182807"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenhalgh</surname><given-names>T</given-names></name><name name-style="western"><surname>Wherton</surname><given-names>J</given-names></name><name name-style="western"><surname>Papoutsi</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies</article-title>. <source>J Med Internet Res</source><year>2017</year>; <volume>19</volume>: <fpage>e367</fpage>. <comment>20171101</comment>.<pub-id pub-id-type="pmid">29092808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/jmir.8775</pub-id><pub-id pub-id-type="pmcid">PMC5688245</pub-id></mixed-citation></ref><ref id="bibr65-20552076231182807"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Celi</surname><given-names>LA</given-names></name><name name-style="western"><surname>Davidzon</surname><given-names>G</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>AE</given-names></name></person-group>, <etal>et al.</etal><article-title>Bridging the health data divide</article-title>. <source>J Med Internet Res</source><year>2016</year>; <volume>18</volume>: <fpage>e325</fpage>. <comment>20161220</comment>.<pub-id pub-id-type="pmid">27998877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/jmir.6400</pub-id><pub-id pub-id-type="pmcid">PMC5209608</pub-id></mixed-citation></ref><ref id="bibr66-20552076231182807"><label>66</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Masoodi</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Andrey</surname><given-names>S</given-names></name><name name-style="western"><surname>Bardeesy</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><comment>Race to trace: security and privacy of COVID-19 contact tracing apps</comment>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cybersecurepolicy.ca/racetotrace" ext-link-type="uri">https://www.cybersecurepolicy.ca/racetotrace</ext-link> (<year>2020</year>, <comment>accessed March 25, 2021 2021</comment>).</mixed-citation></ref><ref id="bibr67-20552076231182807"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooley</surname><given-names>ME</given-names></name><name name-style="western"><surname>Lundin</surname><given-names>R</given-names></name><name name-style="western"><surname>Murray</surname><given-names>L</given-names></name></person-group>. <article-title>Smoking cessation interventions in cancer care: opportunities for oncology nurses and nurse scientists</article-title>. <source>Annu Rev Nurs Res</source><year>2009</year>; <volume>27</volume>: <fpage>243</fpage>&#8211;<lpage>272</lpage>. <comment>2009/01/01</comment>.<pub-id pub-id-type="pmid">20192107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1891/0739-6686.27.243</pub-id><pub-id pub-id-type="pmcid">PMC4729378</pub-id></mixed-citation></ref><ref id="bibr68-20552076231182807"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>R</given-names></name></person-group>. <article-title>The clinical significance of &#8216;small&#8217; effects of smoking cessation treatments</article-title>. <source>Addiction</source><year>2007</year>; <volume>102</volume>: <fpage>506</fpage>&#8211;<lpage>509</lpage>.<pub-id pub-id-type="pmid">17362283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1360-0443.2007.01750.x</pub-id></mixed-citation></ref><ref id="bibr69-20552076231182807"><label>69</label><mixed-citation publication-type="book"><collab>Health Canada</collab>. <source>Seizing the opportunity: the future of tobacco control in Canada</source>. <publisher-loc>Ottawa, ON</publisher-loc>: <publisher-name>Health Canada</publisher-name>, <year>2016</year>.</mixed-citation></ref><ref id="bibr70-20552076231182807"><label>70</label><mixed-citation publication-type="other"><comment>Smoke-Free Ontario Modernization: Report of the executive steering committee. 2017</comment>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>